{
    "clinical_study": {
        "@rank": "163089", 
        "arm_group": [
            {
                "arm_group_label": "Glucagon-Like Peptide -1 (GLP-1) infusion", 
                "arm_group_type": "Active Comparator", 
                "description": "Infusion of GLP-1 during experimental period"
            }, 
            {
                "arm_group_label": "Saline Infusion", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Saline infusion during experimental period"
            }
        ], 
        "brief_summary": {
            "textblock": "Low blood sugar can negatively affect how blood vessels function, and this can lead to an\n      increase in the risk for heart attacks, strokes and other problems related to the stiffening\n      and blockage of blood vessels.  The purpose of this study is to learn if and how\n      glucagon-like peptide-1 (GLP-1; a naturally occurring hormone in the gut) changes the\n      effects that low blood sugar levels have on blood vessels."
        }, 
        "brief_title": "GLP-1 and Hypoglycemia", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Hypoglycemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  14 (7 males, 7 females) healthy controls age 30-60 yr.\n\n          -  14 (7 males, 7 females) people with type 2 DM age 30-60 yr.\n\n          -  For type 2 DM: HbA1c  6-10.0%\n\n          -  No significant diabetic tissue complications (i.e. history of retinopathy,\n             neuropathy, stasis ulcers, etc.)\n\n          -  Body mass index  >25kg \u2022 m-2\n\n        Exclusion Criteria:\n\n        -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01858896", 
            "org_study_id": "HP00055308"
        }, 
        "intervention": [
            {
                "arm_group_label": "Glucagon-Like Peptide -1 (GLP-1) infusion", 
                "description": "GLP-1 infusion during experimental period", 
                "intervention_name": "Glucagon-Like Peptide- 1 (GLP-1) infusion", 
                "intervention_type": "Drug", 
                "other_name": "GLP-1"
            }, 
            {
                "arm_group_label": "Saline Infusion", 
                "description": "Saline infusion (placebo) during experimental period", 
                "intervention_name": "Placebo Comparator: Saline Infusion", 
                "intervention_type": "Other", 
                "other_name": "Saline infusion"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glucagon", 
                "Glucagon-Like Peptide 1"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "hypoglycemia", 
            "GLP-1", 
            "Type 2 diabetes", 
            "endothelial function"
        ], 
        "lastchanged_date": "December 16, 2013", 
        "location": {
            "contact": {
                "last_name": "Donna Tate", 
                "phone": "410-706-5643"
            }, 
            "contact_backup": {
                "last_name": "Nino Joy, MD", 
                "phone": "410-706-5636"
            }, 
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21201"
                }, 
                "name": "University of Maryland, Baltimore"
            }, 
            "investigator": {
                "last_name": "Stephen N Davis, MBBS", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Hypoglycemia Associated Autonomic Dysfunction", 
        "overall_contact": {
            "email": "diabetesstudies@medicine.umaryland.edu", 
            "last_name": "Donna Tate", 
            "phone": "410-706-5643"
        }, 
        "overall_contact_backup": {
            "email": "diabetesstudies@medicine.umaryland.edu", 
            "last_name": "Cheryl Young, CRNP", 
            "phone": "410-706-5641"
        }, 
        "overall_official": {
            "affiliation": "University of Maryland, Baltimore County", 
            "last_name": "Stephen N Davis, MBBS", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "measurements of change in PAi-1 at baseline and during the end of the glucose clamp period (2 hours)", 
                "measure": "Change in Plasminogen Activation inhibitor-1 (PAi-1)", 
                "safety_issue": "No", 
                "time_frame": "change from baseline to end of clamp period"
            }, 
            {
                "description": "flow mediated dilation of the brachial artery will be measured for change from baseline and end of glucose clamp (~4 hours)", 
                "measure": "Change in Flow mediated dilation (FMD)", 
                "safety_issue": "No", 
                "time_frame": "change from baseline and end of clamp"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01858896"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Maryland", 
            "investigator_full_name": "Stephen N. Davis", 
            "investigator_title": "Chairman of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "University of Maryland", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Maryland", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}